Hedge funds regain appetite for US stocks, feel full of Europe, Asia
NEW YORK (Reuters) -Global hedge funds started to add back U.S. equities to portfolios last week following a massive selloff in Wall Street's major indexes, an early indication of optimism about the c
EM Stocks Set for Best Month Since September on China Boost
(Bloomberg) -- Emerging-market equities are set to extend their best monthly performance since September as a rebound in Chinese shares gain momentum on more fiscal measures.Most Read from BloombergIC
Stocks Haven’t Traded at These Levels Since September
Market gains that started last fall, when polls showed President Trump taking a narrow lead in the election, have been erased.
Options Market Signals Stability After Brisk S&P 500 Selloff
(Bloomberg) -- A sign of stability is emerging after the S&P 500 Index plunged into one of its sharpest-ever corrections: Traders are ditching bets that another deep slide is ahead.Most Read from Bloo
Rapid euro zone house market recovery raises affordability concerns, ECB says
The euro zone housing market has already recovered from its recent slump and prices are likely to rise further, challenging affordability in a potentially unhealthy development, the European Central B
3 Reasons NOVT is Risky and 1 Stock to Buy Instead
Novanta’s stock price has taken a beating over the past six months, shedding 21.9% of its value and falling to a new 52-week low of $133.58 per share. This was partly due to its softer quarterly res
3 Reasons to Sell USM and 1 Stock to Buy Instead
Over the past six months, U.S. Cellular has been a great trade. While the S&P 500 was flat, the stock price has climbed by 13.9% to $64.40 per share. This was partly thanks to its solid quarterly resu
3 Reasons LYTS is Risky and 1 Stock to Buy Instead
LSI currently trades at $17.32 and has been a dream stock for shareholders. It’s returned 485% since March 2020, blowing past the S&P 500’s 122% gain. The company has also beaten the index over th
3 Reasons to Avoid CBZ and 1 Stock to Buy Instead
CBIZ has been treading water for the past six months, recording a small return of 2.4% while holding steady at $69.40.
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.